BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19728760)

  • 1. Activation of HLA-G expression by 5-aza-2 - deoxycytidine in malignant hematopoetic cells isolated from leukemia patients.
    Polakova K; Bandzuchova E; Sabty FA; Mistrik M; Demitrovicova L; Russ G
    Neoplasma; 2009; 56(6):514-20. PubMed ID: 19728760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demethylating agent 5-aza-2'-deoxycytidine activates HLA-G expression in human leukemia cell lines.
    Poláková K; Bandzuchová E; Kuba D; Russ G
    Leuk Res; 2009 Apr; 33(4):518-24. PubMed ID: 18823661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of HLA-G expression in malignant hematopoetic cells from leukemia patients.
    Poláková K; Krcová M; Kuba D; Russ G
    Leuk Res; 2003 Jul; 27(7):643-8. PubMed ID: 12681364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 5-aza-2'-deoxycytidine on immune-associated proteins in exosomes from hepatoma.
    Xiao WH; Sanren GW; Zhu JH; Li QW; Kang HR; Wang RL; Song LP; Ye M
    World J Gastroenterol; 2010 May; 16(19):2371-7. PubMed ID: 20480522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas.
    Nie Y; Yang G; Song Y; Zhao X; So C; Liao J; Wang LD; Yang CS
    Carcinogenesis; 2001 Oct; 22(10):1615-23. PubMed ID: 11577000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of HLA-G expression.
    Polakova K; Bandzuchova E; Tirpakova J; Kuba D; Russ G
    Neoplasma; 2007; 54(6):455-62. PubMed ID: 17949227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2'-deoxycytidine.
    Yan WH; Lin AF; Chang CC; Ferrone S
    Cell Res; 2005 Jul; 15(7):523-31. PubMed ID: 16045815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of HLA-G in patients with B-cell chronic lymphocytic leukemia (B-CLL).
    Giannopoulos K; Dmoszyńska A; Bojarska-Junak A; Schmitt M; Roliński J
    Folia Histochem Cytobiol; 2008; 46(4):457-60. PubMed ID: 19141398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia.
    Claus R; Pfeifer D; Almstedt M; Zucknick M; Hackanson B; Plass C; Lübbert M
    Leuk Res; 2013 Feb; 37(2):190-6. PubMed ID: 23158571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-G gene repression is reversed by demethylation.
    Moreau P; Mouillot G; Rousseau P; Marcou C; Dausset J; Carosella ED
    Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1191-6. PubMed ID: 12552087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of 5-aza-2'-deoxycytidine on the amount of exosomes and secreted immuno-associated proteins by hepatoma cells].
    Sanrengaowa ; Wu Y; Xiao WH
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):495-9. PubMed ID: 19950695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
    Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
    Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
    Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
    Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.
    Dubovsky JA; McNeel DG; Powers JJ; Gordon J; Sotomayor EM; Pinilla-Ibarz JA
    Clin Cancer Res; 2009 May; 15(10):3406-15. PubMed ID: 19401350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.
    Flotho C; Claus R; Batz C; Schneider M; Sandrock I; Ihde S; Plass C; Niemeyer CM; Lübbert M
    Leukemia; 2009 Jun; 23(6):1019-28. PubMed ID: 19194470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo.
    Zhou J; Li Y; Yao Y; Wang L; Gao L; Gao X; Luo X; Li J; Jiang M; Zhou M; Wang L; Yu L
    Mol Med Rep; 2013 Nov; 8(5):1549-55. PubMed ID: 24002123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidine.
    Dubovsky JA; Powers JJ; Gao Y; Mariusso LF; Sotomayor EM; Pinilla-Ibarz JA
    Leuk Res; 2011 Sep; 35(9):1193-9. PubMed ID: 21377729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The study of 5-Aza-2'-deoxycytidine on transcription regulation of p16/CDKN2 gene demethylation in RKO human colorectal cell line].
    Fang XM; Sun LF; Peng JP; Dong Q; Zheng S
    Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2077-82. PubMed ID: 14703421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Udaka K; Yokoyama A
    Leuk Res; 2011 Jul; 35(7):932-9. PubMed ID: 21550660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
    Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
    Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.